Compare Divis Laboratories with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs AUROBINDO PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES AUROBINDO PHARMA DIVIS LABORATORIES/
AUROBINDO PHARMA
 
P/E (TTM) x 33.0 11.5 286.6% View Chart
P/BV x 10.5 1.4 747.4% View Chart
Dividend Yield % 0.5 0.8 71.5%  

Financials

 DIVIS LABORATORIES   AUROBINDO PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-21
AUROBINDO PHARMA
Mar-21
DIVIS LABORATORIES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,9131,023 382.5%   
Low Rs1,824333 547.2%   
Sales per share (Unadj.) Rs262.5422.8 62.1%  
Earnings per share (Unadj.) Rs74.792.0 81.3%  
Cash flow per share (Unadj.) Rs84.4110.0 76.7%  
Dividends per share (Unadj.) Rs20.004.00 500.0%  
Avg Dividend yield %0.70.6 118.2%  
Book value per share (Unadj.) Rs350.1374.3 93.5%  
Shares outstanding (eoy) m265.47585.94 45.3%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x10.91.6 681.2%   
Avg P/E ratio x38.47.4 520.4%  
P/CF ratio (eoy) x34.06.2 551.3%  
Price / Book Value ratio x8.21.8 452.1%  
Dividend payout %26.84.3 615.2%   
Avg Mkt Cap Rs m761,517397,398 191.6%   
No. of employees `000NANA-   
Total wages/salary Rs m8,25835,350 23.4%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m69,694247,746 28.1%  
Other income Rs m6273,809 16.5%   
Total revenues Rs m70,321251,555 28.0%   
Gross profit Rs m28,61181,480 35.1%  
Depreciation Rs m2,55610,554 24.2%   
Interest Rs m21745 2.8%   
Profit before tax Rs m26,66073,990 36.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,81820,098 33.9%   
Profit after tax Rs m19,84353,892 36.8%  
Gross profit margin %41.132.9 124.8%  
Effective tax rate %25.627.2 94.1%   
Net profit margin %28.521.8 130.9%  
BALANCE SHEET DATA
Current assets Rs m67,906198,235 34.3%   
Current liabilities Rs m17,284106,652 16.2%   
Net working cap to sales %72.637.0 196.5%  
Current ratio x3.91.9 211.4%  
Inventory Days Days1019 49.6%  
Debtors Days Days87852 1,701.2%  
Net fixed assets Rs m45,963135,778 33.9%   
Share capital Rs m531586 90.6%   
"Free" reserves Rs m92,415218,713 42.3%   
Net worth Rs m92,946219,299 42.4%   
Long term debt Rs m01,684 0.0%   
Total assets Rs m113,869334,013 34.1%  
Interest coverage x1,270.5100.3 1,266.4%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.7 82.5%   
Return on assets %17.416.4 106.6%  
Return on equity %21.324.6 86.9%  
Return on capital %28.733.8 84.9%  
Exports to sales %053.8 0.0%   
Imports to sales %18.816.4 114.9%   
Exports (fob) Rs mNA133,248 0.0%   
Imports (cif) Rs m13,12740,615 32.3%   
Fx inflow Rs m58,877133,248 44.2%   
Fx outflow Rs m13,34144,946 29.7%   
Net fx Rs m45,53688,302 51.6%   
CASH FLOW
From Operations Rs m19,46933,289 58.5%  
From Investments Rs m7515,987 12.5%  
From Financial Activity Rs m-349-13,648 2.6%  
Net Cashflow Rs m19,87225,831 76.9%  

Share Holding

Indian Promoters % 51.9 48.8 106.5%  
Foreign collaborators % 0.0 3.1 -  
Indian inst/Mut Fund % 36.8 38.3 96.0%  
FIIs % 18.5 20.8 88.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 48.1 48.2 99.8%  
Shareholders   309,397 338,639 91.4%  
Pledged promoter(s) holding % 0.0 14.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   SUN PHARMA    CIPLA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    

Yellow Ad

Advertisement

A One Stock Gift in 1990 Turns into Rs 130 Crores

In 2017, Ravi made headlines by calling a leading business news channel with a surprising announcement - his grandfather had left him 20,000 shares of only one stock.

And on the day of his call - these shares were worth Rs 130 crore.

Can you guess which is this company?

It's MRF.

Ravi's story is one of the amazing stories of becoming Crorepati from a single stock.

But the question is, how to find that one stock with crorepati potential?

To find the answer to this million-dollar question, join our 'One Stock Crorepati' MEGA summit on 30th June, where we will reveal details of what we call a potential 'crorepati' stock...

Learn more



Today's Market

Sensex Zooms 462 Points, Nifty Ends Near 15,700; Auto & FMCG Stocks Rally(Closing)

Indian share markets ended the week on a firm note tracking positive global cues.

Related Views on News

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Aurobindo Pharma Rallies on Sale of Injectables Unit to Subsidiary (Views On News)

Jul 2, 2021

Here's why the company sold its business unit to Eugia Pharma Specialities.

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks(Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Why Tata Power Share Price is Falling(Views On News)

Jun 14, 2022

Here's why shares of Tata Power have fallen in recent days.

Is it Time to Start Buying Stocks Selectively?(Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

Best Monopoly Stocks to Own in 2022(Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

When Will the Stock Market Recover?(Views On News)

Jun 15, 2022

This is how you can tell the market is going to recover.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jun 24, 2022 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - RELISH PHARMA COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS